Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00464113
Status:
TERMINATED
Last Update Posted:
2015-08-21
First Post:
2007-04-18
Brief Title:
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
Sponsor:
Exelixis
Organization:
Exelixis
Study Overview
Official Title:
A Phase 1 Dose-Escalation Study of the Safety Pharmacokinetics and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia CML or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia Ph ALL
Status:
TERMINATED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228 how often it should be taken and how well people with leukemia tolerate XL228
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None